Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially.

Pissani F, Malherbe DC, Robins H, DeFilippis VR, Park B, Sellhorn G, Stamatatos L, Overbaugh J, Haigwood NL.

Vaccine. 2012 Aug 10;30(37):5519-26. doi: 10.1016/j.vaccine.2012.06.042. Epub 2012 Jun 27.

2.

Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.

Sellhorn G, Kraft Z, Caldwell Z, Ellingson K, Mineart C, Seaman MS, Montefiori DC, Lagerquist E, Stamatatos L.

J Virol. 2012 Jan;86(1):128-42. doi: 10.1128/JVI.06363-11. Epub 2011 Oct 26.

3.

Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16.

Davenport TM, Friend D, Ellingson K, Xu H, Caldwell Z, Sellhorn G, Kraft Z, Strong RK, Stamatatos L.

J Virol. 2011 Jul;85(14):7095-107. doi: 10.1128/JVI.00411-11. Epub 2011 May 4.

4.

Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes.

Blish CA, Sather DN, Sellhorn G, Stamatatos L, Sun Y, Srivastava I, Barnett SW, Cleveland B, Overbaugh J, Hu SL.

J Virol. 2010 Mar;84(5):2573-84. doi: 10.1128/JVI.01687-09. Epub 2009 Dec 16.

5.

Interactions between lipids and human anti-HIV antibody 4E10 can be reduced without ablating neutralizing activity.

Xu H, Song L, Kim M, Holmes MA, Kraft Z, Sellhorn G, Reinherz EL, Stamatatos L, Strong RK.

J Virol. 2010 Jan;84(2):1076-88. doi: 10.1128/JVI.02113-09. Epub 2009 Nov 11.

6.

Improving the expression of recombinant soluble HIV Envelope glycoproteins using pseudo-stable transient transfection.

Sellhorn G, Caldwell Z, Mineart C, Stamatatos L.

Vaccine. 2009 Dec 11;28(2):430-6. doi: 10.1016/j.vaccine.2009.10.028. Epub 2009 Oct 24.

PMID:
19857451
7.

Physcomitrella patens has lipoxygenases for both eicosanoid and octadecanoid pathways.

Anterola A, Göbel C, Hornung E, Sellhorn G, Feussner I, Grimes H.

Phytochemistry. 2009 Jan;70(1):40-52. doi: 10.1016/j.phytochem.2008.11.012. Epub 2009 Jan 7.

PMID:
19131081
8.

Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.

Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, Yu X, Wood B, Self S, Kalams S, Stamatatos L.

J Virol. 2009 Jan;83(2):757-69. doi: 10.1128/JVI.02036-08. Epub 2008 Nov 5. Erratum in: J Virol. 2009 May;83(9):4713-5.

9.

Crystal structures of vegetative soybean lipoxygenase VLX-B and VLX-D, and comparisons with seed isoforms LOX-1 and LOX-3.

Youn B, Sellhorn GE, Mirchel RJ, Gaffney BJ, Grimes HD, Kang C.

Proteins. 2006 Dec 1;65(4):1008-20.

Supplemental Content

Loading ...
Support Center